Clay Siegall: The sturdy Entrepreneur
Seattle Genetics which is co-owned by Clay Siegall is regarded as the largest biotech in Washington with a market value of $10billion and 900 employees under its wings. The company hopes to graduate from being a biotech company and become a big pharmaceutical. The company invests in research and marketing and has an ambitious plan of employing 200 more people to its payroll.
Siegall’s focus is not on drug development, but being able to handle the pressure that comes with marketing new drugs internationally. To showcase its ambitions, the company recently opened a new Switzerland office that will permit it to do its own international marketing.
The 18-year-old company has been on a steep growth trajectory as its stock price has tripled in the last five years from $20 to $66 a share. The company has close to 11 drugs on its pipeline due to be released with four of them expected to be a big hit with the consumers. These drugs include; adcetris that is a drug for Hodgkin lymphoma, 33A that is used for myeloid leukemia, 22ME that seeks to cure bladder cancer and lastly LIVI that is aimed at curing breast cancer. The company hopes to soar to great heights and its ambitious Chief Executive Officer is bound to get it there.
ABOUT CLAY SIEGALL:
Clay Siegall assisted to co-find Seattle Genetics, Inc and has held the position of a CEO since 2002. Siegall has spent 20 years conducting research on cancer and drug development that is therapeutic. He has gained considerable experience from working as a Senior Research Investigator with Bristol-Myers Squibb Pharmaceutical Research Institute and Ultragenyx Pharmaceutical Inc. as its director.
Clay Siegall serves on various boards such as; the WBBA. Dr.Siegall is part of the Board of Scientific Counselors for the Cancer Treatment Research Foundation. He also served Mirna Therapeutics as a non-executive director for three years. He has been a staff fellow at National Institute of Health and National Cancer Institute.
Clay Siegall has successfully published 67 scientific papers and is known to hold nine patents. In 1995, Clay Siegall was recognized for his hard work in the field of targeted toxins by being awarded a Pierce Award. He also appeared as a finalist in an Ernst &Young Pacific Northwest Entrepreneur Award in the category of healthcare.
For his education, Clay Siegal attended George Washington University where he attained a Ph.D. in Genetics. He also attended the University of Maryland where he achieved a B.S in Zoology.